Quick Answer
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Total Revenue of $1.25 million for fiscal year 2024.
Cordyceps Sunshine Biotech Holdings Co., Ltd. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $1.25M +42.0% |
$882.5K +1555.7% |
$53.3K -93.9% |
$879.3K | — |
| Net Income | -$226.3K -130.1% |
$751.6K +204.4% |
-$720.1K -46.7% |
-$491.0K | — |
| Diluted EPS | $0.00 -100.0% |
$0.01 +200.0% |
-$0.01 | $0.00 | — |
| Total Assets | $4.62M +37.9% |
$3.35M +59.2% |
$2.10M -35.5% |
$3.26M +15.5% |
$2.83M |
| Cash and Equivalents | $37.3K +61.4% |
$23.1K +248.6% |
$6.6K -93.4% |
$99.7K +33806.1% |
$294.00 |
| Long-Term Debt | — | $431.1K +4.1% |
$414.0K | — | — |
| Stockholders Equity | -$375.5K -147.4% |
-$151.8K +84.0% |
-$951.3K -244.9% |
-$275.8K -2052.8% |
-$12.8K |
| R&D Expense | — | — | $118.4K +372.8% |
$25.1K | — |
| Operating Income | -$183.9K -180.7% |
$227.8K +154.9% |
-$415.1K -247.7% |
-$119.4K | — |
| Gross Profit | $533.8K -30.4% |
$766.4K +1837.4% |
$39.6K +122.4% |
-$176.2K | — |
| Shares Outstanding | 111.12M +0.0% |
111.12M +0.0% |
111.12M +0.0% |
111.12M +0.0% |
111.12M |
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Total Revenue of $1.25 million for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +42.0% in Total Revenue compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Net Income of -$226.3 thousand for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed a decrease of -130.1% in Net Income compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Diluted EPS of $0.00 per share for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed a decrease of -100.0% in Diluted EPS compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Total Assets of $4.62 million for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +37.9% in Total Assets compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Cash and Equivalents of $37.3 thousand for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +61.4% in Cash and Equivalents compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Long-Term Debt of $431.1 thousand for fiscal year 2023.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +4.1% in Long-Term Debt compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Stockholders Equity of -$375.5 thousand for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed a decrease of -147.4% in Stockholders Equity compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported R&D Expense of $118.4 thousand for fiscal year 2022.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +372.8% in R&D Expense compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Operating Income of -$183.9 thousand for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed a decrease of -180.7% in Operating Income compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Gross Profit of $533.8 thousand for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed a decrease of -30.4% in Gross Profit compared to the prior fiscal year.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Shares Outstanding of 111.12 million shares for fiscal year 2024.
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: